BioLife Solutions Stock Price, News & Analysis (NASDAQ:BLFS) $13.25 +0.88 (+7.11%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$11.91▼$13.3050-Day Range$8.99▼$14.0852-Week Range$8.92▼$26.89Volume2.24 million shsAverage Volume554,939 shsMarket Capitalization$583.40 millionP/E RatioN/ADividend YieldN/APrice Target$24.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media BioLife Solutions MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside85.7% Upside$24.60 Price TargetShort InterestBearish9.40% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.90Based on 3 Articles This WeekInsider TradingAcquiring Shares$10.37 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.06) to ($0.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector516th out of 957 stocksElectromedical Equipment Industry13th out of 23 stocks 3.5 Analyst's Opinion Consensus RatingBioLife Solutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.60, BioLife Solutions has a forecasted upside of 85.7% from its current price of $13.25.Amount of Analyst CoverageBioLife Solutions has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.40% of the outstanding shares of BioLife Solutions have been sold short.Short Interest Ratio / Days to CoverBioLife Solutions has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in BioLife Solutions has recently increased by 4.55%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBioLife Solutions does not currently pay a dividend.Dividend GrowthBioLife Solutions does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLFS. Previous Next 2.7 News and Social Media Coverage News SentimentBioLife Solutions has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BioLife Solutions this week, compared to 2 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioLife Solutions insiders have bought 1,358.50% more of their company's stock than they have sold. Specifically, they have bought $10,374,976.00 in company stock and sold $711,344.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of BioLife Solutions is held by insiders.Percentage Held by Institutions93.24% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioLife Solutions are expected to grow in the coming year, from ($1.06) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLife Solutions is -5.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLife Solutions is -5.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLife Solutions has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioLife Solutions Stock (NASDAQ:BLFS)BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; ultra-low temperature mechanical freezers; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.Read More BLFS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLFS Stock News HeadlinesNovember 29, 2023 | seekingalpha.comBioLife Solutions: A Complicated TaleNovember 27, 2023 | americanbankingnews.comComparing Endonovo Therapeutics (OTCMKTS:ENDV) & BioLife Solutions (NASDAQ:BLFS)December 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 22, 2023 | morningstar.comBioLife Solutions Inc BLFSNovember 17, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Vigil Neuroscience Inc (VIGL), Medicine Man Technologies (OtherSHWZ) and BioLife Solutions (BLFS)November 17, 2023 | msn.comBioLife Solutions files to sell 927.2K shares for holdersNovember 16, 2023 | finance.yahoo.comBioLife Solutions (BLFS) was Impacted by Inventory Destocking and Elongated Sales CyclesNovember 16, 2023 | finance.yahoo.comAnalysts Just Shaved Their BioLife Solutions, Inc. (NASDAQ:BLFS) Forecasts DramaticallyDecember 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 11, 2023 | markets.businessinsider.comNorthland Securities Reaffirms Their Buy Rating on BioLife Solutions (BLFS)November 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and GoodRx Holdings (GDRX)November 10, 2023 | finance.yahoo.comBioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | seekingalpha.comBioLife Solutions, Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 9, 2023 | benzinga.comBioLife Solns: Q3 Earnings InsightsNovember 9, 2023 | finance.yahoo.comBioLife Solutions Reports Third Quarter 2023 Financial ResultsNovember 8, 2023 | markets.businessinsider.comHere's what Wall Street expects from Biolife Solutions's earnings reportNovember 3, 2023 | bizjournals.comBioLife Solutions raises $10.4M through private placementNovember 2, 2023 | finance.yahoo.comBioLife Solutions to Provide Third Quarter 2023 Financial Results and Business Update on November 9, 2023November 2, 2023 | finance.yahoo.comFormer CEO Michael Rice Sells 72,603 Shares of BioLife Solutions IncOctober 24, 2023 | msn.comBioLife Solutions says Casdin Partners Master Fund buys 927.2K shares in coOctober 20, 2023 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on BioLife Solutions (BLFS)October 19, 2023 | marketwatch.comBioLife Solutions Taps Roderick de Greef as Chairman, CEOOctober 19, 2023 | msn.comBioLife Solutions expects FY revenue at low end of guidance, names new CEO; shares fallOctober 19, 2023 | finance.yahoo.comBioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023October 6, 2023 | msn.comBioLife Plasma hiring for upcoming Lubbock donation centerOctober 5, 2023 | finance.yahoo.comShareholders in BioLife Solutions (NASDAQ:BLFS) are in the red if they invested three years agoSeptember 22, 2023 | fool.comBioLife Solutions (NASDAQ: BLFS)See More Headlines Receive BLFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/03/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLFS CUSIPN/A CIK834365 Webwww.biolifesolutions.com Phone(425) 402-1400Fax425-402-1433Employees466Year FoundedN/APrice Target and Rating Average Stock Price Target$24.60 High Stock Price Target$28.00 Low Stock Price Target$22.00 Potential Upside/Downside+85.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,800,000.00 Net Margins-66.04% Pretax Margin-65.96% Return on Equity-12.70% Return on Assets-10.26% Debt Debt-to-Equity Ratio0.07 Current Ratio2.74 Quick Ratio1.72 Sales & Book Value Annual Sales$161.76 million Price / Sales3.61 Cash FlowN/A Price / Cash FlowN/A Book Value$7.54 per share Price / Book1.76Miscellaneous Outstanding Shares44,030,000Free Float42,842,000Market Cap$583.40 million OptionableNot Optionable Beta1.61 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Roderick de Greef (Age 63)CEO & Chairman Comp: $635.85kMr. Troy Wichterman (Age 38)Chief Financial Officer Comp: $508.89kDr. Aby J. Mathew Ph.D. (Age 51)Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer Comp: $543.46kMr. Michael P. Rice (Age 60)Consultant Comp: $1.03MMs. Karen Foster (Age 63)Chief Quality Officer Comp: $452.95kMr. Geraint PhillipsSenior Vice President of Global OperationsMr. Todd Berard (Age 54)Chief Marketing Officer Comp: $286.49kMs. Sarah Aebersold J.D. (Age 46)Chief Human Resources Officer Mr. Garrie Richardson B.Sc.M.B.A., Chief Revenue OfficerMore ExecutivesKey CompetitorsZynexNASDAQ:ZYXISoleno TherapeuticsNASDAQ:SLNOAxoGenNASDAQ:AXGNSemler ScientificNASDAQ:SMLROutset MedicalNASDAQ:OMView All CompetitorsInsiders & InstitutionsDeutsche Bank AGSold 55,742 shares on 11/24/2023Ownership: 0.045%Public Sector Pension Investment BoardSold 19,243 shares on 11/22/2023Ownership: 0.096%Spears Abacus Advisors LLCSold 1,450 shares on 11/21/2023Ownership: 0.062%Comerica BankBought 18,734 shares on 11/21/2023Ownership: 0.043%Tudor Investment Corp Et AlBought 74,949 shares on 11/16/2023Ownership: 0.170%View All Insider TransactionsView All Institutional Transactions BLFS Stock Analysis - Frequently Asked Questions Should I buy or sell BioLife Solutions stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BLFS shares. View BLFS analyst ratings or view top-rated stocks. What is BioLife Solutions' stock price target for 2024? 5 Wall Street analysts have issued 12 month price objectives for BioLife Solutions' shares. Their BLFS share price targets range from $22.00 to $28.00. On average, they anticipate the company's stock price to reach $24.60 in the next twelve months. This suggests a possible upside of 85.7% from the stock's current price. View analysts price targets for BLFS or view top-rated stocks among Wall Street analysts. How have BLFS shares performed in 2023? BioLife Solutions' stock was trading at $18.20 at the beginning of the year. Since then, BLFS shares have decreased by 27.2% and is now trading at $13.25. View the best growth stocks for 2023 here. When is BioLife Solutions' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our BLFS earnings forecast. How were BioLife Solutions' earnings last quarter? BioLife Solutions, Inc. (NASDAQ:BLFS) issued its quarterly earnings data on Thursday, November, 9th. The medical equipment provider reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.09. The medical equipment provider had revenue of $33.33 million for the quarter, compared to the consensus estimate of $33.28 million. BioLife Solutions had a negative net margin of 66.04% and a negative trailing twelve-month return on equity of 12.70%. What guidance has BioLife Solutions issued on next quarter's earnings? BioLife Solutions issued an update on its third quarter 2023 earnings guidance on Thursday, October, 19th. The company provided EPS guidance of for the period. The company issued revenue guidance of $33.30 million-$33.30 million, compared to the consensus revenue estimate of $32.72 million. What is Mike Rice's approval rating as BioLife Solutions' CEO? 14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend. What other stocks do shareholders of BioLife Solutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM). Who are BioLife Solutions' major shareholders? BioLife Solutions' stock is owned by many different institutional and retail investors. Top institutional investors include Fred Alger Management LLC (4.11%), Invesco Ltd. (2.42%), William Blair Investment Management LLC (1.55%), Ameriprise Financial Inc. (1.22%), New York State Common Retirement Fund (0.96%) and Jennison Associates LLC (0.93%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Geraint Phillips, Greef Roderick De, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Sarah Aebersold, Todd Berard, Troy Wichterman and Walter Villiger. View institutional ownership trends. How do I buy shares of BioLife Solutions? Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:BLFS) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLife Solutions, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.